BRAIN Biotech AG (XTRA: BNN)
Materials · Chemicals · DE
€2.65
-6.36% today · +20.5% 1Y
BRAIN Biotech AG (XTRA: BNN) operates in the Chemicals industry within the Materials sector. The company is valued at $67.59M and employs 280 people.
Over the last twelve months the share price has gained 20.5%, trading between 2.00 and 3.89.
Tweenvest scores BRAIN Biotech AG across four factors: quality 23/100, value 52/100, growth 51/100. Its strongest factor is value.
BNN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $67.59M
- Revenue (TTM)
- $55.70M
- P/E
- —
- EPS
- -0.51
- Dividend yield
- —
- Beta (5Y)
- 0.63
- 52-week high
- €3.89
- 52-week low
- €2.00
- Avg volume (3M)
- —
- Shares outstanding
- 21.85M
- Employees
- 280
- Next earnings
- —
About BRAIN Biotech AG
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.
- ISIN
- DE0005203947
- Founded
- 1993
- Listed since
- Feb 9, 2016
- Exchange
- XETRA Trading Platform
- Currency
- EUR
Other Chemicals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Linde plcNasdaqGS: LIN | $224.59B | $485.12 | -0.43% |
| L'Air Liquide S.A.ENXTPA: AI | $124.62B | €168.88 | +0.66% |
| The Sherwin-Williams CompanyNYSE: SHW | $84.57B | $350.99 | +0.15% |
| Ecolab Inc.NYSE: ECL | $81.17B | $289.86 | +0.11% |
| Shin-Etsu Chemical Co., Ltd.TSE: 4063 | $70.11B | ¥6,005.00 | -0.76% |
| Air Products and Chemicals, Inc.NYSE: APD | $67.66B | $303.85 | -0.78% |
| Corteva, Inc.NYSE: CTVA | $55.41B | $82.96 | -0.11% |
| BASF SEXTRA: BAS | $51.92B | €52.01 | +0.64% |
Figures last refreshed Aug 18, 2026.